# ![@BioTechHealthX Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1387526045134462978.png) @BioTechHealthX BioTech Health X

BioTech Health X posts on X about health, nasdaq, strong, stocks the most. They currently have [---] followers and [---] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1387526045134462978/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1387526045134462978/c:line/m:interactions.svg)

- [--] Week [-----] +181%
- [--] Month [-----] -4.80%
- [--] Months [------] +224%
- [--] Year [------] +6,857%

### Mentions: [--] [#](/creator/twitter::1387526045134462978/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1387526045134462978/c:line/m:posts_active.svg)

- [--] Month [--] -52%
- [--] Months [---] +390%
- [--] Year [---] +8,775%

### Followers: [---] [#](/creator/twitter::1387526045134462978/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1387526045134462978/c:line/m:followers.svg)

- [--] Week [---] +2.50%
- [--] Month [---] +3.80%
- [--] Months [---] +23%
- [--] Year [---] +46%

### CreatorRank: [---------] [#](/creator/twitter::1387526045134462978/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1387526045134462978/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  67.83% [finance](/list/finance)  37.39% [exchanges](/list/exchanges)  18.26% [cryptocurrencies](/list/cryptocurrencies)  5.22% [technology brands](/list/technology-brands)  3.48%

**Social topic influence**
[health](/topic/health) 100%, [nasdaq](/topic/nasdaq) #830, [strong](/topic/strong) 10.43%, [stocks](/topic/stocks) 8.7%, [growth](/topic/growth) 5.22%, [future](/topic/future) 4.35%, [target](/topic/target) 4.35%, [the most](/topic/the-most) 3.48%, [company](/topic/company) 3.48%, [market](/topic/market) 3.48%

**Top accounts mentioned or mentioned by**
[@instilbio](/creator/undefined) [@axsome](/creator/undefined) [@achievelifesci](/creator/undefined) [@dbvtechnologies](/creator/undefined) [@cytekbio](/creator/undefined) [@annovisbio](/creator/undefined) [@unicycive](/creator/undefined) [@exelixisinc](/creator/undefined) [@cgoncology](/creator/undefined) [@iovancebio](/creator/undefined) [@allogenetx](/creator/undefined) [@monterosatx](/creator/undefined) [@calcimedicainc](/creator/undefined) [@fda](/creator/undefined) [@legendbiotech](/creator/undefined) [@aviditybio](/creator/undefined) [@kyvernatx](/creator/undefined) [@4dmolecular](/creator/undefined) [@cingulateinc](/creator/undefined) [@immixbiopharma](/creator/undefined)

**Top assets mentioned**
[Ocular Therapeutix, Inc. (OCUL)](/topic/$ocul) [Candel Therapeutics, Inc. (CADL)](/topic/$cadl) [Prelude Therapeutics Inc. (PRLD)](/topic/$prld) [Axsome Therapeutics, Inc (AXSM)](/topic/$axsm) [Instil Bio, Inc. (TIL)](/topic/$til) [Muhdo Hub (DNA)](/topic/$dna) [UnitedHealth Group (UNH)](/topic/$unh) [AbCellera Biologics Inc. (ABCL)](/topic/$abcl) [Cytek Biosciences, Inc. (CTKB)](/topic/$ctkb) [Greenwich LifeSciences, Inc. (GLSI)](/topic/$glsi) [Structure Therapeutics Inc. (GPCR)](/topic/$gpcr) [Acadia Healthcare Company, Inc. (ACHC)](/topic/$achc) [Annovis Bio Inc. (ANVS)](/topic/$anvs) [Unicycive Therapeutics, Inc. (UNCY)](/topic/$uncy) [Exelixis Inc (EXEL)](/topic/$exel) [CG Oncology, Inc.  (CGON)](/topic/$cgon) [Iovance Biotherapeutics, Inc. Common Stock (IOVA)](/topic/$iova) [Allora (ALLO)](/topic/$allo) [Context Therapeutics Inc. (CNTX)](/topic/$cntx) [Monte Rosa Therapeutics, Inc. (GLUE)](/topic/$glue) [CalciMedica, Inc. (CALC)](/topic/calcimedica-inc) [Legend Biotech Corp (LEGN)](/topic/$legn) [Oric Pharmaceuticals, Inc. (ORIC)](/topic/$oric) [Harmony Biosciences Holdings, Inc. (HRMY)](/topic/$hrmy) [Cullinan Management, Inc. (CGEM)](/topic/$cgem) [Avidity Biosciences, Inc. (RNA)](/topic/$rna) [Kyverna Therapeutics, Inc. (KYTX)](/topic/$kytx) [4D Molecular Therapeutics Inc. (FDMT)](/topic/$fdmt) [Cingulate Inc. (CING)](/topic/cingulate-inc) [Immix Biopharma, Inc.  (IMMX)](/topic/$immx) [Humana Inc (HUM)](/topic/humana-inc) [Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)](/topic/$teva) [Elevance Health Inc (ELV)](/topic/$elv) [McKesson Corporation (MCK)](/topic/mckesson) [HCA Healthcare Inc (HCA)](/topic/$hca) [Molina Healthcare, Inc. (MOH)](/topic/$moh)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$EXEL While hype-driven biotech stocks burn cash @ExelixisInc stock keeps delivering real oncology revenue. Heres why NASDAQ: EXEL is quietly becoming a long-term winner. https://biotechhealthx.com/biotech-news/exelixis-exel-isnt-a-flashy-biotech-its-the-one-quietly-making-billions/ https://biotechhealthx.com/biotech-news/exelixis-exel-isnt-a-flashy-biotech-its-the-one-quietly-making-billions/"  
[X Link](https://x.com/BioTechHealthX/status/2014757215098503409)  2026-01-23T17:48Z [---] followers, [---] engagements


"$CGON @cgoncology (NASDAQ:CGON) is quietly emerging as one of the most talked-about biotech stocks in oncology. From its focused bladder cancer mission to its growing investor attention heres why CGON is landing on watchlists everywhere. https://biotechhealthx.com/biotech-news/is-this-the-next-breakout-biotech-why-cg-oncology-cgon-is-suddenly-on-smart-investors-radar/ https://biotechhealthx.com/biotech-news/is-this-the-next-breakout-biotech-why-cg-oncology-cgon-is-suddenly-on-smart-investors-radar/"  
[X Link](https://x.com/BioTechHealthX/status/2015465605424660681)  2026-01-25T16:43Z [---] followers, [---] engagements


"$IOVA Real-world outcomes can make or break a biotech launch and Iovance is putting numbers on the board. Learn what the latest advanced melanoma data suggests about Amtagvi why treatment timing matters and how expanding treatment centers and manufacturing could unlock the next leg for @IovanceBio. https://biotechhealthx.com/biotech-news/44-real-world-response-iovance-iova-just-made-off-the-bench-data-the-new-headline/ https://biotechhealthx.com/biotech-news/44-real-world-response-iovance-iova-just-made-off-the-bench-data-the-new-headline/"  
[X Link](https://x.com/BioTechHealthX/status/2022525279370121281)  2026-02-14T04:16Z [---] followers, [---] engagements


"$ALLO Investors searching ALLO stock and allogeneic CAR T are hunting one answer: can off-the-shelf CAR-T become routine medicine This deep dive frames the bullish thesis around ALPHA3 MRD clearance in large B-cell lymphoma ALLO-329 in autoimmune disease and the manufacturing scale argument that could turn @AllogeneTx from a niche bet into a category trade. https://biotechhealthx.com/biotech-news/the-market-cap-is-small-the-idea-is-huge-can-allogene-allo-make-car-t-as-easy-as-ordering-a-drug/"  
[X Link](https://x.com/BioTechHealthX/status/2022525602411221474)  2026-02-14T04:17Z [---] followers, [--] engagements


"$CADL Candel Therapeutics Inc. (NASDAQ:CADL) is one of those small-caps that can flip the narrative fastbecause its not pitching theory. Its lead program has reported Phase [--] prostate cancer results with a statistically significant endpoint win and the company is pointing to a clear regulatory runway that investors can actually calendar. https://biotechhealthx.com/biotech-news/the-290m-cancer-biotech-with-phase-3-proof-candel-cadls-viral-immunotherapy-isnt-just-a-science-fair-anymore/"  
[X Link](https://x.com/BioTechHealthX/status/2022529456926265594)  2026-02-14T04:32Z [---] followers, [---] engagements


"$CNTX Context Therapeutics Inc. (NASDAQ: CNTX) did what most small-cap biotechs wontkilled the old story and rebuilt around T cell engager bispecific antibodies for solid tumors. With a $223.27M market cap and leverage at 30.90% CNTX is a classic platform re-rating candidate heading into [----] oncology catalysts and Phase [--] data updates. https://biotechhealthx.com/biotech-news/context-cntxs-glow-up-from-old-thesis-to-t-cell-engager-chaos-in-a-good-way/ https://biotechhealthx.com/biotech-news/context-cntxs-glow-up-from-old-thesis-to-t-cell-engager-chaos-in-a-good-way/"  
[X Link](https://x.com/BioTechHealthX/status/2022529608625852594)  2026-02-14T04:33Z [---] followers, [--] engagements


"$PRLD Prelude Therapeutics Incorporated (NASDAQ:PRLD) is leveraging targeted protein degradation and next generation discovery to design novel precision cancer medicines. This article explores Prelude Therapeutics origins strategy and why the companys clinical development direction is getting new attention across precision oncology investing. https://biotechhealthx.com/biotech-news/is-prelude-therapeutics-prld-the-next-precision-medicine-breakout/ https://biotechhealthx.com/biotech-news/is-prelude-therapeutics-prld-the-next-precision-medicine-breakout/"  
[X Link](https://x.com/BioTechHealthX/status/2005069657037037831)  2025-12-28T00:13Z [---] followers, [---] engagements


"$TIL @InstilBio Inc (NASDAQ:TIL) recently restructured its development focus and the implications could be far bigger than the headlines suggest. Heres what this strategic reset really means for the future of the company and its stock. https://biotechhealthx.com/biotech-news/instil-bio-inc-nasdaqtil-just-reset-its-strategy-and-that-could-change-everything/ https://biotechhealthx.com/biotech-news/instil-bio-inc-nasdaqtil-just-reset-its-strategy-and-that-could-change-everything/"  
[X Link](https://x.com/BioTechHealthX/status/2008546721673212097)  2026-01-06T14:30Z [---] followers, [---] engagements


"$GLUE With its molecular glue degrader platform @MonteRosaTx (NASDAQ: GLUE) is working on therapies designed to eliminate disease-causing proteins rather than just inhibit them. Discover what makes GLUE stock a unique biotech opportunity. https://biotechhealthx.com/biotech-news/monte-rosa-therapeutics-glue-is-targeting-diseases-other-drugs-cant-touch/ https://biotechhealthx.com/biotech-news/monte-rosa-therapeutics-glue-is-targeting-diseases-other-drugs-cant-touch/"  
[X Link](https://x.com/BioTechHealthX/status/2008904973002875201)  2026-01-07T14:14Z [---] followers, [--] engagements


"$CALC @CalciMedicaInc (NASDAQ:CALC) isnt chasing crowded drug trends. Its going after calcium signaling in inflammationand that focus could define its future. https://biotechhealthx.com/biotech-news/calcimedica-calc-high-risk-biotech-or-deep-science-sleeper/ https://biotechhealthx.com/biotech-news/calcimedica-calc-high-risk-biotech-or-deep-science-sleeper/"  
[X Link](https://x.com/BioTechHealthX/status/2012948523625619696)  2026-01-18T18:01Z [---] followers, [---] engagements


"$LEGN With expanding @FDA approvals growing manufacturing capacity and strong pharma partnerships @LegendBiotech Corporation (NASDAQ:LEGN) stands out as a high-quality CAR-T company with durable competitive advantages. https://biotechhealthx.com/biotech-news/legend-biotech-legn-could-be-one-of-the-smartest-car-t-bets-in-biotech-right-now/ https://biotechhealthx.com/biotech-news/legend-biotech-legn-could-be-one-of-the-smartest-car-t-bets-in-biotech-right-now/"  
[X Link](https://x.com/BioTechHealthX/status/2014749024231031279)  2026-01-23T17:16Z [---] followers, [---] engagements


"$ORIC With short interest climbing and analysts staying bullish ORIC Pharmaceuticals sits at the center of a rare biotech disconnect. We break down what the market sees and what it may be ignoring. https://biotechhealthx.com/biotech-news/23-of-traders-are-short-this-oncology-stock-heres-what-they-might-be-missing-about-oric-pharma-oric/ https://biotechhealthx.com/biotech-news/23-of-traders-are-short-this-oncology-stock-heres-what-they-might-be-missing-about-oric-pharma-oric/"  
[X Link](https://x.com/BioTechHealthX/status/2014749300467892579)  2026-01-23T17:17Z [---] followers, [--] engagements


"$HRMY As most biotech stocks burn cash Harmony Biosciences continues to grow revenue and profits. Discover what makes NASDAQ: HRMY one of the sectors quiet outperformers. https://biotechhealthx.com/biotech-news/harmony-biosciences-hrmy-keeps-beating-expectations-while-biotech-struggles/ https://biotechhealthx.com/biotech-news/harmony-biosciences-hrmy-keeps-beating-expectations-while-biotech-struggles/"  
[X Link](https://x.com/BioTechHealthX/status/2014753498429292748)  2026-01-23T17:34Z [---] followers, [--] engagements


"$CGEM As clinical data matures and regulatory milestones approach Cullinan Therapeutics Inc. (NASDAQ: CGEM) may transition from a cash-burn narrative to a value-creation story. https://biotechhealthx.com/biotech-news/cullinan-therapeutics-cgem-could-be-the-biotech-stock-the-market-mispriced/ https://biotechhealthx.com/biotech-news/cullinan-therapeutics-cgem-could-be-the-biotech-stock-the-market-mispriced/"  
[X Link](https://x.com/BioTechHealthX/status/2014753619531440282)  2026-01-23T17:34Z [---] followers, [---] engagements


"$RNA @aviditybio (NASDAQ:RNA) is still unprofitable yet the stock continues to surge. Heres why the market may be betting on its antibody-oligonucleotide conjugate platform over short-term earnings. https://biotechhealthx.com/biotech-news/heres-why-avidity-biosciences-rna-keeps-hitting-new-highs-despite-being-unprofitable/ https://biotechhealthx.com/biotech-news/heres-why-avidity-biosciences-rna-keeps-hitting-new-highs-despite-being-unprofitable/"  
[X Link](https://x.com/BioTechHealthX/status/2014757388784734550)  2026-01-23T17:49Z [---] followers, [--] engagements


"$KYTX @Kyverna_Tx (NASDAQ:KYTX) isnt chasing hype its chasing immune reset. Discover why this biotech stock is emerging as a leader in autoimmune CAR-T therapy. https://biotechhealthx.com/biotech-news/kyverna-therapeutics-kytx-is-being-called-the-autoimmune-car-t-pioneer/ https://biotechhealthx.com/biotech-news/kyverna-therapeutics-kytx-is-being-called-the-autoimmune-car-t-pioneer/"  
[X Link](https://x.com/BioTechHealthX/status/2015465412318904667)  2026-01-25T16:42Z [---] followers, [--] engagements


"$FDMT @4DMolecular (NASDAQ:FDMT) is sitting on a massive cash runway while advancing gene therapy trials. FDMT stock however suggests the market isnt convinced yetand that tension is getting interesting. https://biotechhealthx.com/biotech-news/this-biotech-has-more-cash-than-confidence-meet-4d-molecular-therapeutics-inc-nasdaqfdmt/ https://biotechhealthx.com/biotech-news/this-biotech-has-more-cash-than-confidence-meet-4d-molecular-therapeutics-inc-nasdaqfdmt/"  
[X Link](https://x.com/BioTechHealthX/status/2015466642948669884)  2026-01-25T16:47Z [---] followers, [---] engagements


"$CING @CingulateInc (NASDAQ:CING) is racing toward a key FDA decision for its ADHD drug but rising cash burn and dilution risks raise tough questions. Is CING stock a breakthrough story or a financial cliff https://biotechhealthx.com/biotech-news/cingulate-cing-is-betting-big-on-adhd-but-is-it-running-out-of-time/ https://biotechhealthx.com/biotech-news/cingulate-cing-is-betting-big-on-adhd-but-is-it-running-out-of-time/"  
[X Link](https://x.com/BioTechHealthX/status/2016547107046625533)  2026-01-28T16:21Z [---] followers, [---] engagements


"$IMMX @Immixbiopharma (NASDAQ: IMMX) is developing a novel CAR-T therapy for AL Amyloidosis a rare but deadly disease with no approved treatments. Heres the story behind the science. https://biotechhealthx.com/biotech-news/this-nasdaq-biotech-is-targeting-a-6-billion-market-no-one-talks-about-meet-immix-biopharma-immx/ https://biotechhealthx.com/biotech-news/this-nasdaq-biotech-is-targeting-a-6-billion-market-no-one-talks-about-meet-immix-biopharma-immx/"  
[X Link](https://x.com/BioTechHealthX/status/2016547250244297031)  2026-01-28T16:21Z [---] followers, [--] engagements


"$HUM @Humana Inc (NYSE:HUM) evolved from hospital ownership into a Medicare Advantage leader positioning itself at the center of U.S. healthcare insurance and value-based care. https://biotechhealthx.com/biotech-news/from-hospitals-to-medicare-dominance-how-humana-hum-built-a-healthcare-empire/ https://biotechhealthx.com/biotech-news/from-hospitals-to-medicare-dominance-how-humana-hum-built-a-healthcare-empire/"  
[X Link](https://x.com/BioTechHealthX/status/2016550898936529336)  2026-01-28T16:36Z [---] followers, [---] engagements


"$TEVA Teva Pharmaceutical Industries Limited (NYSE: TEVA) is reinventing itself with a powerful mix of generics specialty drugs and biosimilars. After years of restructuring this pharma stock is drawing fresh investor attention. https://biotechhealthx.com/biotech-news/this-120-year-old-pharma-giant-is-suddenly-hot-again-teva-pharmaceutical-teva/ https://biotechhealthx.com/biotech-news/this-120-year-old-pharma-giant-is-suddenly-hot-again-teva-pharmaceutical-teva/"  
[X Link](https://x.com/BioTechHealthX/status/2016551063940481470)  2026-01-28T16:36Z [---] followers, [--] engagements


"$ELV @ElevanceHealth (NYSE: ELV) is deeply embedded in U.S. healthcare from Medicaid to Medicare Advantage. This article explores why ELV stock remains a sleeper giant in the market. https://biotechhealthx.com/biotech-news/elevance-health-elv-touches-millions-every-day-yet-it-rarely-makes-headlines/ https://biotechhealthx.com/biotech-news/elevance-health-elv-touches-millions-every-day-yet-it-rarely-makes-headlines/"  
[X Link](https://x.com/BioTechHealthX/status/2016551212494303506)  2026-01-28T16:37Z [---] followers, [--] engagements


"$MCK With consistent revenue growth massive free cash flow and favorable analyst sentiment @McKesson Corporation (NYSE:MCK) is emerging as a compelling healthcare investment opportunity. https://biotechhealthx.com/biotech-news/wall-street-sees-nearly-15-upside-in-mckesson-corporation-mck-heres-why/ https://biotechhealthx.com/biotech-news/wall-street-sees-nearly-15-upside-in-mckesson-corporation-mck-heres-why/"  
[X Link](https://x.com/BioTechHealthX/status/2017625743610810374)  2026-01-31T15:47Z [---] followers, [--] engagements


"$HCA Raised price targets solid EBITDA performance and disciplined expense management are reshaping the investment case for @HCAhealthcare (NYSE:HCA). https://biotechhealthx.com/biotech-news/hca-healthcare-hca-is-acting-like-a-defensive-growth-stock-and-analysts-agree/ https://biotechhealthx.com/biotech-news/hca-healthcare-hca-is-acting-like-a-defensive-growth-stock-and-analysts-agree/"  
[X Link](https://x.com/BioTechHealthX/status/2017625892252749989)  2026-01-31T15:47Z [---] followers, [--] engagements


"$MOH Investor expectations for Medicare Advantage rates triggered a sector-wide sell-off yet Molina Healthcare (NYSE:MOH) remains deeply embedded in government-sponsored healthcare programs with long-term demand visibility. https://biotechhealthx.com/biotech-news/healthcare-stocks-sold-off-fast-but-molina-healthcare-moh-may-be-misunderstood/ https://biotechhealthx.com/biotech-news/healthcare-stocks-sold-off-fast-but-molina-healthcare-moh-may-be-misunderstood/"  
[X Link](https://x.com/BioTechHealthX/status/2017626058930196834)  2026-01-31T15:48Z [---] followers, [---] engagements


"$PRLD Prelude Therapeutics surged after the FDA cleared its IND for PRT12396 a mutant-selective JAK2 inhibitor targeting high-risk blood cancers. We explain why this regulatory milestone could reshape PRLDs clinical trajectory and investor sentiment. https://biotechhealthx.com/biotech-news/is-it-a-wise-choice-to-invest-in-prelude-therapeutics-prld/ https://biotechhealthx.com/biotech-news/is-it-a-wise-choice-to-invest-in-prelude-therapeutics-prld/"  
[X Link](https://x.com/BioTechHealthX/status/2019734131295568277)  2026-02-06T11:25Z [---] followers, [--] engagements


"$GRI GRI Bio Inc. has delivered strong Phase 2a data in idiopathic pulmonary fibrosis while extending its cash runway into [----]. With real clinical proof RNA-sequencing validation and a strengthened balance sheet NASDAQ: GRI may be entering a very different risk category than investors assume. https://biotechhealthx.com/biotech-news/should-you-now-consider-investing-in-gri-bio-gri/ https://biotechhealthx.com/biotech-news/should-you-now-consider-investing-in-gri-bio-gri/"  
[X Link](https://x.com/BioTechHealthX/status/2019734274673439230)  2026-02-06T11:25Z [---] followers, [---] engagements


"$CANF @CanFitePharma (NYSE:CANF) reported a real-world case where its oral drug Namodenoson stabilized a critically ill liver patient long enough for a successful transplant. Could this overlooked biotech be sitting on a high-impact medical breakthrough the market hasnt priced in yet https://biotechhealthx.com/biotech-news/is-it-a-great-time-to-buy-can-fite-biopharma-canf-shares/ https://twitter.com/i/web/status/2019734444610101515 https://biotechhealthx.com/biotech-news/is-it-a-great-time-to-buy-can-fite-biopharma-canf-shares/ https://twitter.com/i/web/status/2019734444610101515"  
[X Link](https://x.com/BioTechHealthX/status/2019734444610101515)  2026-02-06T11:26Z [---] followers, [--] engagements


"$DNA @Ginkgo Bioworks Inc. ranks 1st in our list of the Top [--] Biotech Stocks With the Biggest Price Gains Today. The company has moved beyond AI buzzwords by deploying a GPT-5-driven autonomous lab that generated nearly [------] data points. The work suggests AI can meaningfully lower costs and improve productivity in real biological experiments. https://biotechhealthx.com/biotech-news/is-ginkgo-bioworks-dna-a-smart-long-term-pick/ https://biotechhealthx.com/biotech-news/is-ginkgo-bioworks-dna-a-smart-long-term-pick/"  
[X Link](https://x.com/BioTechHealthX/status/2019735809507934509)  2026-02-06T11:31Z [---] followers, [---] engagements


"$IBRX @ImmunityBio (NASDAQ:IBRX) is drawing attention as its immunotherapy story gains real-world traction. We break down whats driving the buzz the growth outlook and the biggest risks investors need to know. https://biotechhealthx.com/biotech-news/is-it-still-worthy-to-buy-immunitybio-ibrx-shares/ https://biotechhealthx.com/biotech-news/is-it-still-worthy-to-buy-immunitybio-ibrx-shares/"  
[X Link](https://x.com/BioTechHealthX/status/2020544783874433358)  2026-02-08T17:06Z [---] followers, [----] engagements


"$AVTX Avalo Therapeutics (NASDAQ:AVTX) is heading toward a high-stakes Phase [--] LOTUS readout in hidradenitis suppurativa and the market loves a clean biotech catalyst. Heres why AVTX stock could reprice fast if AVTX-009 delivers real efficacy and a workable safety profile. https://biotechhealthx.com/biotech-news/avalo-therapeutics-avtxs-next-5-minutes-of-fame-the-hs-data-drop-that-could-shock-traders/ https://biotechhealthx.com/biotech-news/avalo-therapeutics-avtxs-next-5-minutes-of-fame-the-hs-data-drop-that-could-shock-traders/"  
[X Link](https://x.com/BioTechHealthX/status/2021995160083759120)  2026-02-12T17:09Z [---] followers, [---] engagements


"$TTRX Turn Therapeutics earns national recognition as one of the Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment. Learn how the GX-03 IL-36targeting technology could disrupt the $20B eczema market ahead of [----] topline data. https://biotechhealthx.com/biotech-news/turn-therapeutics-ttrx-named-top-innovator-in-atopic-dermatitis-with-gx-03-breakthrough/ https://biotechhealthx.com/biotech-news/turn-therapeutics-ttrx-named-top-innovator-in-atopic-dermatitis-with-gx-03-breakthrough/"  
[X Link](https://x.com/BioTechHealthX/status/1992807669586092361)  2025-11-24T04:09Z [---] followers, [---] engagements


"$AVIR Atea Pharmaceuticals Inc (NASDAQ:AVIR) has completed enrollment in a major Phase [--] hepatitis C trial setting the stage for pivotal mid-2026 data that could reshape the antiviral treatment landscape. https://biotechhealthx.com/biotech-news/why-atea-pharmaceuticals-inc-avir-could-be-entering-its-most-important-phase-yet/ https://biotechhealthx.com/biotech-news/why-atea-pharmaceuticals-inc-avir-could-be-entering-its-most-important-phase-yet/"  
[X Link](https://x.com/BioTechHealthX/status/2003694137619677533)  2025-12-24T05:08Z [---] followers, [---] engagements


"$SLNO Soleno Therapeutics Inc (NASDAQ:SLNO) is focused on precision therapies for rare diseases. This article explains why SLNOs long-term story might be more important than it looks. https://biotechhealthx.com/biotech-news/soleno-therapeutics-slno-might-be-building-something-bigger-than-most-investors-realize/ https://biotechhealthx.com/biotech-news/soleno-therapeutics-slno-might-be-building-something-bigger-than-most-investors-realize/"  
[X Link](https://x.com/BioTechHealthX/status/2011119932860514310)  2026-01-13T16:55Z [---] followers, [---] engagements


"$AXSM @axsome Therapeutics Inc. (NASDAQ:AXSM) built its business around CNS disorders that big pharma abandoned and that contrarian focus may be exactly why its growth story keeps surprising investors. https://biotechhealthx.com/biotech-news/why-axsome-therapeutics-axsm-keeps-winning-in-a-part-of-pharma-everyone-else-quit/ https://biotechhealthx.com/biotech-news/why-axsome-therapeutics-axsm-keeps-winning-in-a-part-of-pharma-everyone-else-quit/"  
[X Link](https://x.com/BioTechHealthX/status/2012948191499399475)  2026-01-18T18:00Z [---] followers, [---] engagements


"$UNH @UnitedHealthGrp Incorporated (NYSE: UNH) adapts to regulatory shifts and cost pressures through scale technology and value-based care making it a cornerstone stock in healthcare investing. https://biotechhealthx.com/biotech-news/heres-why-unitedhealth-group-unh-keeps-winning-while-healthcare-keeps-changing/ https://biotechhealthx.com/biotech-news/heres-why-unitedhealth-group-unh-keeps-winning-while-healthcare-keeps-changing/"  
[X Link](https://x.com/BioTechHealthX/status/2016546914939089201)  2026-01-28T16:20Z [---] followers, [---] engagements


"$ABT $UNH $JNJ $ISRG $MDT From Abbott Laboratories (NYSE:ABT) to UnitedHealth Group (NYSE:UNH) and Johnson & Johnson (NYSE:JNJ) healthcare companies continue to benefit from non-discretionary demand aging populations and innovation-driven growth. https://biotechhealthx.com/biotech-news/heres-why-healthcare-equipment-and-services-keep-winning-even-when-markets-panic/ https://biotechhealthx.com/biotech-news/heres-why-healthcare-equipment-and-services-keep-winning-even-when-markets-panic/"  
[X Link](https://x.com/BioTechHealthX/status/2016890360635805931)  2026-01-29T15:05Z [---] followers, [---] engagements


"$DNA $AEMD $ABCL $SXTC $THAR $PLSE $CANF $TOI $GRI $PRLD Biotech stocks often surge on news tied to clinical progress and regulatory updates. Learn why breakthroughs in drug discovery genetics and AI are translating into rapid price action across the sector today. https://biotechhealthx.com/biotech-news/top-10-biotech-stocks-with-the-biggest-price-gains-today/ https://biotechhealthx.com/biotech-news/top-10-biotech-stocks-with-the-biggest-price-gains-today/"  
[X Link](https://x.com/BioTechHealthX/status/2019726253046284302)  2026-02-06T10:53Z [---] followers, [---] engagements


"$ABCL Despite trading at depressed levels @AbCelleraBio Biologics continues to earn Buy ratings from analysts. This article explores why NASDAQ: ABCLs platform pipeline progress and upcoming earnings could challenge the markets https://biotechhealthx.com/biotech-news/heres-why-wall-street-still-says-buy-even-as-abcellera-abcl-trades-like-a-penny-stock/ https://biotechhealthx.com/biotech-news/heres-why-wall-street-still-says-buy-even-as-abcellera-abcl-trades-like-a-penny-stock/"  
[X Link](https://x.com/BioTechHealthX/status/2019735356711875051)  2026-02-06T11:30Z [---] followers, [---] engagements


"$CMPX Compass Therapeutics (NASDAQ:CMPX) is on biotech watchlists as oncology data and upcoming catalysts drive interest. Heres what investors are watching why the setup matters and where risk lives. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-acquire-compass-therapeutics-cmpx-shares/ https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-acquire-compass-therapeutics-cmpx-shares/"  
[X Link](https://x.com/BioTechHealthX/status/2020544982415999166)  2026-02-08T17:07Z [---] followers, [---] engagements


"$ADMA @AdmaBiologics (NASDAQ:ADMA) emerges as our top biotech stock for February [----] supported by rising profitability expanding plasma supply and strong earnings visibility. https://biotechhealthx.com/biotech-news/adma-biologics-adma-1-biotech-stock-pick-for-february-2026/ https://biotechhealthx.com/biotech-news/adma-biologics-adma-1-biotech-stock-pick-for-february-2026/"  
[X Link](https://x.com/BioTechHealthX/status/2020545223311700250)  2026-02-08T17:08Z [---] followers, [---] engagements


"$MBRX $ACHV $AVTX $DBVT $MNMD [----] is packed with Phase [--] results Phase [--] topline data and FDA decision dates that can reprice biotech stocks fast. This watchlist screens NYSE/NASDAQ names under $2B market cap and ranks the top [--] by market capbuilt for investors hunting asymmetric upside. (@achievelifesci @Avalo Therapeutics @DBVTechnologies @MindMedicineAU @moleculinbio) https://biotechhealthx.com/biotech-news/top-5-best-biotech-micro-caps-with-major-clinical-catalysts-in-2026/ https://biotechhealthx.com/biotech-news/top-5-best-biotech-micro-caps-with-major-clinical-catalysts-in-2026/"  
[X Link](https://x.com/BioTechHealthX/status/2021872037598515261)  2026-02-12T09:00Z [---] followers, [---] engagements


"$DBVT Long before exposure management became a buzzword in tech @DBVTechnologies was already chasing exposure in immunologycontrolled micro-exposures through the skin via the VIASKIN platform. Learn the background behind the epicutaneous immunotherapy story driving DBVT stock interest. https://biotechhealthx.com/biotech-news/dbv-technologies-dbvt-didnt-chase-a-fad-it-built-a-category-the-peanut-allergy-patch/ https://biotechhealthx.com/biotech-news/dbv-technologies-dbvt-didnt-chase-a-fad-it-built-a-category-the-peanut-allergy-patch/"  
[X Link](https://x.com/BioTechHealthX/status/2021995010468786678)  2026-02-12T17:09Z [---] followers, [--] engagements


"$ACHV @achievelifesci (NASDAQ: ACHV) is chasing one of the biggest public-health markets in biotech: nicotine dependence treatment. Heres why cytisinicline the June [--] [----] PDUFA timeline and a massive quit-smoking opportunity have investors watching closely. https://biotechhealthx.com/biotech-news/achieve-life-sciences-achv-has-a-june-2026-make-or-break-date-is-this-the-smoking-cessation-biotech-everyones-early-on/ https://biotechhealthx.com/biotech-news/achieve-life-sciences-achv-has-a-june-2026-make-or-break-date-is-this-the-smoking-cessation-biotech-everyones-early-on/"  
[X Link](https://x.com/BioTechHealthX/status/2021995296717488412)  2026-02-12T17:10Z [---] followers, [--] engagements


"$NUVB @nuvationbioinc (NYSE: NUVB) is no longer just a clinical-stage storyits FDA-approved oncology launch is producing trackable momentum with patient starts stacking quarter after quarter. Heres why that matters for precision oncology investors hunting [----] biotech catalysts. https://biotechhealthx.com/biotech-news/nuvation-nuvbs-quiet-launch-isnt-quiet-anymore-the-patient-start-numbers-that-got-biotech-watching/ https://biotechhealthx.com/biotech-news/nuvation-nuvbs-quiet-launch-isnt-quiet-anymore-the-patient-start-numbers-that-got-biotech-watching/"  
[X Link](https://x.com/BioTechHealthX/status/2022524876230472028)  2026-02-14T04:14Z [---] followers, [--] engagements


"$CMPX Compass Therapeutics Inc. (NASDAQ: CMPX) has randomized Phase 2/3 traction in aggressive biliary tract cancer and a near-term PFS/OS moment that can re-rate the story fast. With a roughly $1.12B market cap and a runway narrative that reduces dilution fear CMPX is one of the more catalyst-loaded oncology biotech stocks to watch in [----]. https://biotechhealthx.com/biotech-news/compass-therapeutics-cmpx-has-a-survival-data-trapdoor-and-2026-might-be-when-it-opens/ https://biotechhealthx.com/biotech-news/compass-therapeutics-cmpx-has-a-survival-data-trapdoor-and-2026-might-be-when-it-opens/"  
[X Link](https://x.com/BioTechHealthX/status/2022525029775442006)  2026-02-14T04:15Z [---] followers, [--] engagements


"$VSTM @VerastemOncolog (NASDAQ: VSTM) has already crossed the line most biotech stocks never reach: an FDA-approved precision oncology launch with real net product revenue momentum. Heres why the [----] setupcommercial execution KRAS-mutated LGSOC focus and RAS/MAPK pipeline optionalitycould trigger a serious re-rating if adoption keeps climbing. https://biotechhealthx.com/biotech-news/verastem-vstm-isnt-small-cap-roulette-anymore-its-a-commercial-oncology-ramp-with-a-2026-twist/"  
[X Link](https://x.com/BioTechHealthX/status/2022525463332294707)  2026-02-14T04:17Z [---] followers, [--] engagements


"$NKTX @nkartatx (NASDAQ: NKTX) isnt chasing crowded oncology anymoreits aiming at B celldriven autoimmune disease with an off-the-shelf CAR-NK therapy. Heres why the pivot matters what immune reset could mean for patients and why [----] data could flip the NKTX narrative fast. https://biotechhealthx.com/biotech-news/nkarta-nktxs-plot-twist-from-cancer-chaos-to-autoimmune-immune-reset-hype/ https://twitter.com/i/web/status/2022529823449714956 https://biotechhealthx.com/biotech-news/nkarta-nktxs-plot-twist-from-cancer-chaos-to-autoimmune-immune-reset-hype/"  
[X Link](https://x.com/BioTechHealthX/status/2022529823449714956)  2026-02-14T04:34Z [---] followers, [--] engagements


"$CADL With $87.2M cash and $130M financing Candel Therapeutics is ready for its first Biologics License Application next year. https://biotechhealthx.com/biotech-news/candel-therapeutics-cadl-boosts-cash-to-217m-prepares-for-2026-prostate-cancer-launch/ https://biotechhealthx.com/biotech-news/candel-therapeutics-cadl-boosts-cash-to-217m-prepares-for-2026-prostate-cancer-launch/"  
[X Link](https://x.com/BioTechHealthX/status/1978440749445255501)  2025-10-15T12:40Z [---] followers, [---] engagements


"$NAMS NewAmsterdam Pharma rockets nearly 94% year-over-year as investors bet big on its late-stage cholesterol drug obicetrapib. https://biotechhealthx.com/biotech-news/newamsterdam-pharma-nams-soars-93-9-in-12-months/ https://biotechhealthx.com/biotech-news/newamsterdam-pharma-nams-soars-93-9-in-12-months/"  
[X Link](https://x.com/BioTechHealthX/status/1978443135391871213)  2025-10-15T12:49Z [---] followers, [---] engagements


"$BMRN Multiple first-in-class therapies fuel consistent cash flow and long-term value for BioMarin Pharmaceutical. Learn about it more here https://biotechhealthx.com/biotech-news/biomarin-bmrns-rare-disease-portfolio-generates-over-2-4-billion-in-annual-revenue/ https://biotechhealthx.com/biotech-news/biomarin-bmrns-rare-disease-portfolio-generates-over-2-4-billion-in-annual-revenue/"  
[X Link](https://x.com/BioTechHealthX/status/1979792565974208940)  2025-10-19T06:11Z [---] followers, [---] engagements


"$SGMT @sagimet trades at $7.77 with analysts targeting $29denifanstat data could trigger a biotech breakout. https://biotechhealthx.com/biotech-news/sagimet-biosciences-sgmt-set-for-273-surge-after-buy-rating/ https://biotechhealthx.com/biotech-news/sagimet-biosciences-sgmt-set-for-273-surge-after-buy-rating/"  
[X Link](https://x.com/BioTechHealthX/status/1982338194868965643)  2025-10-26T06:47Z [---] followers, [---] engagements


"$NMRA @Amgen's major ownership signals high confidence in @NeumoraTxs neuroscience pipeline. Check this out https://biotechhealthx.com/biotech-news/neumora-therapeutics-nmra-backed-by-amgen-with-22-stake/ https://biotechhealthx.com/biotech-news/neumora-therapeutics-nmra-backed-by-amgen-with-22-stake/"  
[X Link](https://x.com/BioTechHealthX/status/1982367646541877270)  2025-10-26T08:44Z [---] followers, [---] engagements


"$EDAP With 167% growth in Focal One installations EDAP TMS is redefining robotic prostate cancer therapy. Check this out https://biotechhealthx.com/biotech-news/why-edap-tms-edap-could-be-the-next-2b-medtech-breakout/ https://biotechhealthx.com/biotech-news/why-edap-tms-edap-could-be-the-next-2b-medtech-breakout/"  
[X Link](https://x.com/BioTechHealthX/status/1986495158234587262)  2025-11-06T18:05Z [---] followers, [---] engagements


"$CTKB @CytekBio is seeing double-digit growth in instrument placements and rising recurring revenue CTKB may be undervalued. https://biotechhealthx.com/biotech-news/why-cytek-biosciences-ctkb-could-be-a-hidden-medtech-gem/ https://biotechhealthx.com/biotech-news/why-cytek-biosciences-ctkb-could-be-a-hidden-medtech-gem/"  
[X Link](https://x.com/BioTechHealthX/status/1987185587888267315)  2025-11-08T15:48Z [---] followers, [---] engagements


"$LFST @lifestanceUS's revenue is up 16% to $363.8 M in Q3 vs $312.7 M a year ago stock jumps as profitability returns. Check this out https://biotechhealthx.com/biotech-news/lifestance-lfst-soars-nearly-30-after-q3-2025-revenue-hits-363-8m/ https://biotechhealthx.com/biotech-news/lifestance-lfst-soars-nearly-30-after-q3-2025-revenue-hits-363-8m/"  
[X Link](https://x.com/BioTechHealthX/status/1987412839116775681)  2025-11-09T06:51Z [---] followers, [--] engagements


"$GMED With $2.X.9 B full-year target & new robotics innovations @GlobusMedical cements leadership in spine & trauma devices. Click here to know more https://biotechhealthx.com/biotech-news/globus-medical-gmed-raises-2025-revenue-guidance-to-2-9-b-heres-what-it-means/ https://biotechhealthx.com/biotech-news/globus-medical-gmed-raises-2025-revenue-guidance-to-2-9-b-heres-what-it-means/"  
[X Link](https://x.com/BioTechHealthX/status/1987412968112595071)  2025-11-09T06:52Z [---] followers, [--] engagements


"$GLSI Greenwich LifeSciences Inc. posted 100% disease-free survival in a key Phase IIb subgroup and insiders recently added US$111K worth of shares. Learn why investors see GLSI as a high-upside clinical-stage opportunity heading into its pivotal Phase III trial. https://biotechhealthx.com/biotech-news/greenwich-lifesciences-reports-100-survival-data-and-heavy-insider-buying/ https://biotechhealthx.com/biotech-news/greenwich-lifesciences-reports-100-survival-data-and-heavy-insider-buying/"  
[X Link](https://x.com/BioTechHealthX/status/1989953692418613554)  2025-11-16T07:08Z [---] followers, [---] engagements


"$JANX Shares of Janux Therapeutics (NASDAQ:JANX) fell to their lowest point since February [----] after updated JANX007 results. But with a 26% PSA90 response and improved CRS safety analysts say the sell-off is overblown. https://biotechhealthx.com/biotech-news/janux-therapeutics-just-hit-its-lowest-price-since-2024-heres-why-wall-street-is-still-bullish/ https://biotechhealthx.com/biotech-news/janux-therapeutics-just-hit-its-lowest-price-since-2024-heres-why-wall-street-is-still-bullish/"  
[X Link](https://x.com/BioTechHealthX/status/1996014818630009155)  2025-12-03T00:33Z [---] followers, [---] engagements


"$OCUL RBC Capital raised OCULs price target to $24 following exceptional SOL-1 patient retention over 95% and no safety concerns. Ocular Therapeutix is now preparing an NDA for AXPAXLI that could redefine long-acting wet AMD therapy. https://biotechhealthx.com/biotech-news/analysts-boost-target-to-24-as-ocular-therapeutix-ocul-nears-major-catalyst/ https://biotechhealthx.com/biotech-news/analysts-boost-target-to-24-as-ocular-therapeutix-ocul-nears-major-catalyst/"  
[X Link](https://x.com/BioTechHealthX/status/1997231371178455338)  2025-12-06T09:07Z [---] followers, [---] engagements


"$CVKD Cadrenal Therapeutics (NASDAQ:CVKD) shocked small cap biotech investors with its Q3 [----] results reporting a $2.7M net loss but major breakthroughs in tecarfarin manufacturing and the expansion of its pipeline through the frunexian acquisition. Discover why analysts are eyeing CVKD as a fast-growing small cap stock with transformative anticoagulation potential. https://biotechhealthx.com/biotech-news/cadrenal-therapeutics-cvkd-surges-in-attention-after-q3-2025-update-reveals-big-pipeline-moves/ https://twitter.com/i/web/status/1997580011100926413"  
[X Link](https://x.com/BioTechHealthX/status/1997580011100926413)  2025-12-07T08:12Z [---] followers, [--] engagements


"$GLSI Unlike traditional oncology drugs Greenwich LifeSciences Inc (NASDAQ:GLSI) is focused on cancer prevention through immunotherapy. Learn how GLSI-100 works why Phase III data matters and what makes this approach different. https://biotechhealthx.com/biotech-news/greenwich-lifesciences-inc-glsi-isnt-treating-cancer-its-trying-to-stop-it-from-coming-back/ https://biotechhealthx.com/biotech-news/greenwich-lifesciences-inc-glsi-isnt-treating-cancer-its-trying-to-stop-it-from-coming-back/"  
[X Link](https://x.com/BioTechHealthX/status/2000545167640789395)  2025-12-15T12:35Z [---] followers, [---] engagements


"$HTLQ Heart Test Laboratories Inc (NASDAQ:HTLQ) focuses on early detection of heart disease using AI-enhanced ECGs offering scalable diagnostics for cardiovascular disease prevention and risk assessment. https://biotechhealthx.com/biotech-news/this-ai-cardiac-screening-stock-targets-the-worlds-1-killer-heart-test-laboratories-inc-htlq/ https://biotechhealthx.com/biotech-news/this-ai-cardiac-screening-stock-targets-the-worlds-1-killer-heart-test-laboratories-inc-htlq/"  
[X Link](https://x.com/BioTechHealthX/status/2003694467992416681)  2025-12-24T05:09Z [---] followers, [--] engagements


"$XENE Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is expanding its lead drug beyond epilepsy into major depressive disorder and bipolar depression potentially unlocking a much larger market for its precision neuroscience platform. https://biotechhealthx.com/biotech-news/from-rare-epilepsy-to-mental-health-why-xenon-pharmaceuticals-xene-is-expanding-fast/ https://biotechhealthx.com/biotech-news/from-rare-epilepsy-to-mental-health-why-xenon-pharmaceuticals-xene-is-expanding-fast/"  
[X Link](https://x.com/BioTechHealthX/status/2006367569234759846)  2025-12-31T14:11Z [---] followers, [---] engagements


"$INSP Explore how @InspireMedical Systems (NYSE:INSP) translated neuroscience research into a commercial medical device now used by physicians worldwide. https://biotechhealthx.com/biotech-news/from-research-lab-to-operating-room-the-rise-of-inspire-medical-systems-insp/ https://biotechhealthx.com/biotech-news/from-research-lab-to-operating-room-the-rise-of-inspire-medical-systems-insp/"  
[X Link](https://x.com/BioTechHealthX/status/2006771830095503840)  2026-01-01T16:57Z [---] followers, [---] engagements


"$APGE With new clinical data and a strong balance sheet Apogee Therapeutics (NASDAQ:APGE) is emerging as a compelling biotech story in immunology and inflammation research. https://biotechhealthx.com/biotech-news/heres-why-apogee-therapeutics-apge-is-suddenly-on-the-radar-of-biotech-investors/ https://biotechhealthx.com/biotech-news/heres-why-apogee-therapeutics-apge-is-suddenly-on-the-radar-of-biotech-investors/"  
[X Link](https://x.com/BioTechHealthX/status/2008550238530015733)  2026-01-06T14:44Z [---] followers, [---] engagements


"$KVUE Defensive stocks arent meant to feel uncomfortable. @kenvue (NYSE:KVUE) is challenging that assumption as risks quietly stack up. https://biotechhealthx.com/biotech-news/kenvue-kvue-was-supposed-to-be-safe-so-why-does-it-feel-risky-now/ https://biotechhealthx.com/biotech-news/kenvue-kvue-was-supposed-to-be-safe-so-why-does-it-feel-risky-now/"  
[X Link](https://x.com/BioTechHealthX/status/2012930674878255543)  2026-01-18T16:50Z [---] followers, [--] engagements


"$GPCR Structure Therapeutics Inc. (NASDAQ:GPCR) is betting that oral GPCR drugs can crack massive metabolic markets that are still dominated by injections and supply constraints. https://biotechhealthx.com/biotech-news/structure-therapeutics-gpcr-is-trying-to-do-what-big-pharma-still-hasnt-turn-obesity-drugs-into-pills/ https://biotechhealthx.com/biotech-news/structure-therapeutics-gpcr-is-trying-to-do-what-big-pharma-still-hasnt-turn-obesity-drugs-into-pills/"  
[X Link](https://x.com/BioTechHealthX/status/2012942665185394920)  2026-01-18T17:38Z [---] followers, [--] engagements


"$ALEC While critics focus on declining sales forecasts Alector Inc. (NASDAQ: ALEC) is building something far bigger beneath the surface targeting immune pathways in neurodegenerative diseases with asymmetric upside few biotech stocks can match. https://biotechhealthx.com/biotech-news/alector-alec-isnt-chasing-revenue-its-chasing-a-breakthrough-the-market-cant-ignore/ https://biotechhealthx.com/biotech-news/alector-alec-isnt-chasing-revenue-its-chasing-a-breakthrough-the-market-cant-ignore/"  
[X Link](https://x.com/BioTechHealthX/status/2014749165549695137)  2026-01-23T17:16Z [---] followers, [--] engagements


"$TECH Hedge funds and institutions dominate @biotechne's shareholder base. We explore why NASDAQ: TECH remains a core holding in long-term life sciences portfolios. https://biotechhealthx.com/biotech-news/nearly-99-institutional-ownership-why-big-money-wont-let-go-of-bio-techne-tech/ https://biotechhealthx.com/biotech-news/nearly-99-institutional-ownership-why-big-money-wont-let-go-of-bio-techne-tech/"  
[X Link](https://x.com/BioTechHealthX/status/2014753958473171048)  2026-01-23T17:35Z [---] followers, [--] engagements


"New interview with Lan Su COO of @LakesideHolding on their strategic growth including Hupan Pharmaceuticals acquisition & partnerships with Sinopharm & Huiyu. Lakeside aims to expand healthcare logistics enhance access & explore new markets. $LSH https://biotechhealthx.com/biotech-ceo-interviews/lan-su-coo-of-lakeside-holding-shares-his-vision-and-strategies-for-charting-new-horizons/ https://biotechhealthx.com/biotech-ceo-interviews/lan-su-coo-of-lakeside-holding-shares-his-vision-and-strategies-for-charting-new-horizons/"  
[X Link](https://x.com/BioTechHealthX/status/1883939189718397435)  2025-01-27T18:04Z [---] followers, [---] engagements


"$HNGE With explosive revenue growth and a bold new provider network @HingeHealth could become the most valuable digital health stock in years. https://biotechhealthx.com/biotech-news/hinge-health-hnge-ipod-big-but-its-just-getting-started/ https://biotechhealthx.com/biotech-news/hinge-health-hnge-ipod-big-but-its-just-getting-started/"  
[X Link](https://x.com/BioTechHealthX/status/1941912445104361632)  2025-07-06T17:29Z [---] followers, [--] engagements


"$LENZ Lenz Therapeutics just made history with the first aceclidine-based eye drop for presbyopia. Lenz' VIZZ could disrupt vision care forever https://biotechhealthx.com/biotech-news/forget-glasses-lenz-therapeutics-lenz-just-got-fda-approval-for-a-daily-eye-drop-fix/ https://biotechhealthx.com/biotech-news/forget-glasses-lenz-therapeutics-lenz-just-got-fda-approval-for-a-daily-eye-drop-fix/"  
[X Link](https://x.com/BioTechHealthX/status/1953134089126694948)  2025-08-06T16:40Z [---] followers, [---] engagements


"$VOR A unique pipeline strong management and a huge addressable market make Vor Biopharma a potential hidden gem for investors. https://biotechhealthx.com/biotech-news/vor-biopharma-vor-could-be-the-most-undervalued-biotech-of-the-year/ https://biotechhealthx.com/biotech-news/vor-biopharma-vor-could-be-the-most-undervalued-biotech-of-the-year/"  
[X Link](https://x.com/BioTechHealthX/status/1955664511341662216)  2025-08-13T16:15Z [---] followers, [---] engagements


"$HCWB HCW Biologics surged after unveiling cutting-edge cancer treatments and strong financial results. Could this be the next biotech rocket https://biotechhealthx.com/biotech-news/hcw-biologics-hcwb-explodes-nearly-100-after-breakthrough-news/ https://biotechhealthx.com/biotech-news/hcw-biologics-hcwb-explodes-nearly-100-after-breakthrough-news/"  
[X Link](https://x.com/BioTechHealthX/status/1960136534809878662)  2025-08-26T00:25Z [---] followers, [--] engagements


"$SMMT Phase III trials confirm ivonescimabs powerful clinical benefit across Asia and Western patients. Summit Therapeutics could dominate the oncology market. https://biotechhealthx.com/biotech-news/summit-therapeutics-smmts-ivonescimab-shows-global-success-analysts-see-billions-ahead/ https://biotechhealthx.com/biotech-news/summit-therapeutics-smmts-ivonescimab-shows-global-success-analysts-see-billions-ahead/"  
[X Link](https://x.com/BioTechHealthX/status/1960349712487514566)  2025-08-26T14:32Z [---] followers, [---] engagements


"$BEAM Beam Therapeutics is trading at oversold levels while sitting on a $1.2B cash pile. Analysts predict massive upside in this company. https://biotechhealthx.com/biotech-news/beam-therapeutics-beam-is-oversold-ready-to-explode-higher/ https://biotechhealthx.com/biotech-news/beam-therapeutics-beam-is-oversold-ready-to-explode-higher/"  
[X Link](https://x.com/BioTechHealthX/status/1963296768810258852)  2025-09-03T17:43Z [---] followers, [--] engagements


"$TIL @InstilBio has surged 180.49% in [--] months crushing the S&P 500s 14.4%. Analysts now eye more momentum as its oncology pipeline advances. https://biotechhealthx.com/biotech-news/instil-bio-til-skyrockets-180-in-one-year/ https://biotechhealthx.com/biotech-news/instil-bio-til-skyrockets-180-in-one-year/"  
[X Link](https://x.com/BioTechHealthX/status/1964732504239485346)  2025-09-07T16:48Z [---] followers, [---] engagements


"$UTHR Tyvaso DPI posted $315.2 million in sales surging 22% YOY and solidifying United Therapeutics leadership in pulmonary hypertension. https://biotechhealthx.com/biotech-news/united-therapeutics-uthr-tyvaso-dpi-sales-hit-315-2m-up-22-yoy/ https://biotechhealthx.com/biotech-news/united-therapeutics-uthr-tyvaso-dpi-sales-hit-315-2m-up-22-yoy/"  
[X Link](https://x.com/BioTechHealthX/status/1964732681423581657)  2025-09-07T16:49Z [---] followers, [---] engagements


"$KMTS @KestraMedical posted $19.4M in Q1 FY26 revenue up 52% year-over-year. Can the ASSURE system push KMTS stock to new highs in [----] https://biotechhealthx.com/biotech-news/kestra-medical-kmts-surges-on-52-revenue-growth/ https://biotechhealthx.com/biotech-news/kestra-medical-kmts-surges-on-52-revenue-growth/"  
[X Link](https://x.com/BioTechHealthX/status/1966887557423337976)  2025-09-13T15:31Z [---] followers, [---] engagements


"$CNTB Connect Biopharma trades at just $1.63 well below its $7.00 @wallstreet target. With 58.72% institutional ownership is a breakout brewing https://biotechhealthx.com/biotech-news/connect-biopharma-cntb-trades-at-1-63-with-7-00-analyst-target/ https://biotechhealthx.com/biotech-news/connect-biopharma-cntb-trades-at-1-63-with-7-00-analyst-target/"  
[X Link](https://x.com/BioTechHealthX/status/1968333010740363372)  2025-09-17T15:15Z [---] followers, [---] engagements


"$ACHC Shares of @AcadiaHealthca1 plunged 71% amid DOJ and SEC probes but activist investor Engine Capitals 3% stake could unlock massive upside. https://biotechhealthx.com/biotech-news/acadia-healthcare-achc-down-71-in-a-year/ https://biotechhealthx.com/biotech-news/acadia-healthcare-achc-down-71-in-a-year/"  
[X Link](https://x.com/BioTechHealthX/status/1970888687270703456)  2025-09-24T16:30Z [---] followers, [--] engagements


"$JAZZ A $905M Chimerix-related charge pushed @JazzPharma into a $505M loss raising investor concerns about its acquisition-driven growth model. https://biotechhealthx.com/biotech-news/jazz-pharma-jazz-reports-905m-rd-charge-505m-net-loss-in-q2-2025/ https://biotechhealthx.com/biotech-news/jazz-pharma-jazz-reports-905m-rd-charge-505m-net-loss-in-q2-2025/"  
[X Link](https://x.com/BioTechHealthX/status/1971601820939432024)  2025-09-26T15:44Z [---] followers, [--] engagements


"$OCUL Ocular Therapeutix offers 37.9M shares at $12.53 securing $475M to advance Axpaxli for wet AMD and NPDR in pivotal Phase [--] studies. https://biotechhealthx.com/biotech-news/ocular-therapeutix-ocul-raises-475m-to-fund-phase-3-axpaxli-trials/ https://biotechhealthx.com/biotech-news/ocular-therapeutix-ocul-raises-475m-to-fund-phase-3-axpaxli-trials/"  
[X Link](https://x.com/BioTechHealthX/status/1974022594962808942)  2025-10-03T08:03Z [---] followers, [---] engagements


"$TARS Tarsus shares jump 10.9% to $65.17 as XDEMVY racks up $181 million in first-half [----] sales one of the fastest-growing eye drop launches. https://biotechhealthx.com/biotech-news/tarsus-pharmaceuticals-tars-skyrockets-10-9-after-181m-xdemvy-sales-surge/ https://biotechhealthx.com/biotech-news/tarsus-pharmaceuticals-tars-skyrockets-10-9-after-181m-xdemvy-sales-surge/"  
[X Link](https://x.com/BioTechHealthX/status/1976143428372086932)  2025-10-09T04:31Z [---] followers, [---] engagements


"$AKRO Akero Therapeutics jumps 16.52% as new clinical data for efruxifermin shows major liver health gains in MASH patients. https://biotechhealthx.com/biotech-news/akero-therapeutics-akro-soars-16-52-after-liver-drug-breakthrough-shocks-wall-street/ https://biotechhealthx.com/biotech-news/akero-therapeutics-akro-soars-16-52-after-liver-drug-breakthrough-shocks-wall-street/"  
[X Link](https://x.com/BioTechHealthX/status/1978047322513871146)  2025-10-14T10:36Z [---] followers, [--] engagements


"$ARTV FDA Fast Track positions Artiva Biotherapeutics to lead a $50 billion autoimmune market. Learn more about this company here https://biotechhealthx.com/biotech-news/artiva-biotherapeutics-artv-rockets-116-in-one-day/ https://biotechhealthx.com/biotech-news/artiva-biotherapeutics-artv-rockets-116-in-one-day/"  
[X Link](https://x.com/BioTechHealthX/status/1979799013584154855)  2025-10-19T06:37Z [---] followers, [--] engagements


"$PMED Picard Medical fell nearly 60% but is still up 15.69% YTD. Investors are betting on a comeback. Learn about it more here https://biotechhealthx.com/biotech-news/picard-medical-pmed-plunges-59-77-in-one-day/ https://biotechhealthx.com/biotech-news/picard-medical-pmed-plunges-59-77-in-one-day/"  
[X Link](https://x.com/BioTechHealthX/status/1982338718964097510)  2025-10-26T06:49Z [---] followers, [---] engagements


"$GNTA @GenentaScience reported improving financials and strong analyst support signaling a bullish trend ahead. https://biotechhealthx.com/biotech-news/genenta-science-gnta-surges-91/ https://biotechhealthx.com/biotech-news/genenta-science-gnta-surges-91/"  
[X Link](https://x.com/BioTechHealthX/status/1982345597802979805)  2025-10-26T07:16Z [---] followers, [--] engagements


"$NNNN Anbio Biotechnology defies volatility with strong growth tech innovation and rising global demand. Click here to learn more https://biotechhealthx.com/biotech-news/anbio-biotechnology-nnnn-surges-142-in-2025/ https://biotechhealthx.com/biotech-news/anbio-biotechnology-nnnn-surges-142-in-2025/"  
[X Link](https://x.com/BioTechHealthX/status/1986488754505457969)  2025-11-06T17:40Z [---] followers, [--] engagements


"$VRDN Three major firms issue Buy ratings on Viridian citing breakthrough data de-risked pipeline and 163% upside potential. https://biotechhealthx.com/biotech-news/heres-why-viridian-therapeutics-vrdn-is-a-strong-buy/ https://biotechhealthx.com/biotech-news/heres-why-viridian-therapeutics-vrdn-is-a-strong-buy/"  
[X Link](https://x.com/BioTechHealthX/status/1987185750677594220)  2025-11-08T15:49Z [---] followers, [---] engagements


"$TNDM @TandemDiabetes's stock jumps as it reports $249 million earnings quarter highest ever for the insulin-pump maker. Check this out https://biotechhealthx.com/biotech-news/tandem-diabetes-care-tndm-hits-249m-q3-revenue-record/ https://biotechhealthx.com/biotech-news/tandem-diabetes-care-tndm-hits-249m-q3-revenue-record/"  
[X Link](https://x.com/BioTechHealthX/status/1987413288037339419)  2025-11-09T06:53Z [---] followers, [--] engagements


"$APYX @ApyxMedical reports 12.1% revenue growth and 64.4% gross margin fueled by AYON sales and record U.S. adoption. Check this out https://biotechhealthx.com/biotech-news/apyx-medical-apyx-surges-15-after-record-q3-revenue-of-12-9m/ https://biotechhealthx.com/biotech-news/apyx-medical-apyx-surges-15-after-record-q3-revenue-of-12-9m/"  
[X Link](https://x.com/BioTechHealthX/status/1987425071137460365)  2025-11-09T07:40Z [---] followers, [---] engagements


"$CTKB @CytekBio (CTKB) jumped 39% in just [--] days after being named to TIMEs [----] Americas Growth Leaders list. With CTKB trading near $5.50 despite industry accolades rising recurring revenue and expanding global adoption investors are asking whether the market is still undervaluing this full-spectrum cytometry powerhouse. https://biotechhealthx.com/biotech-news/cytek-bio-ctkb-surges-39-in-1-month-after-time-2026-recognition/ https://twitter.com/i/web/status/1990632503611109505 https://biotechhealthx.com/biotech-news/cytek-bio-ctkb-surges-39-in-1-month-after-time-2026-recognition/"  
[X Link](https://x.com/BioTechHealthX/status/1990632503611109505)  2025-11-18T04:05Z [---] followers, [---] engagements


"$OLMA Olema Pharmaceuticals (NASDAQ:OLMA) gained massive investor attention after Roche announced positive Phase [--] results for giredestrant validating the same drug class as Olemas lead therapy palazestrant. Learn why this breakthrough could dramatically increase OLMAs probability of trial success and long-term valuation. https://biotechhealthx.com/biotech-news/olema-pharma-olma-surges-after-roches-phase-3-win-validates-oral-serds/ https://biotechhealthx.com/biotech-news/olema-pharma-olma-surges-after-roches-phase-3-win-validates-oral-serds/"  
[X Link](https://x.com/BioTechHealthX/status/1991020732500095341)  2025-11-19T05:48Z [---] followers, [---] engagements


"$ANVS @AnnovisBio (NYSE:ANVS) secured $6M through a 4000000-share direct offering at $1.50 each. With late-stage Alzheimers and Parkinsons trials advancing investors are watching whether ANVS is preparing for a major rebound in [----]. https://biotechhealthx.com/biotech-news/annovis-bio-anvs-raises-6m-at-1-50-share/ https://biotechhealthx.com/biotech-news/annovis-bio-anvs-raises-6m-at-1-50-share/"  
[X Link](https://x.com/BioTechHealthX/status/1991661748601123274)  2025-11-21T00:15Z [---] followers, [---] engagements


"$SRZN @surrozen (NASDAQ:SRZN) is gaining investor attention after reporting $81.3M in cash and advancing its breakthrough Wnt-modulating drug candidates SZN-8141 and SZN-8143. With IND filing planned for [----] and preclinical data showing normal retinal vessel regrowth in diabetic macular edema and wet AMD models SRZN is positioning itself as one of the most compelling small-cap biotech opportunities in [----]. https://biotechhealthx.com/biotech-news/surrozen-srzn-surges-as-wnt-regeneration-pipeline-targets-wet-amd-and-dme/"  
[X Link](https://x.com/BioTechHealthX/status/1993552383688032643)  2025-11-26T05:28Z [---] followers, [---] engagements


"$ANVS @AnnovisBio (NASDAQ:ANVS) surged after Director Michael Hoffman purchased [-----] shares worth $159886 at prices between $3.85 and $4.15. With the stock now at $4.42 and up 21.36% in one week insider accumulation and a 106.57% six-month rally raise the question: is ANVS gearing up for a major biotech run https://biotechhealthx.com/biotech-news/annovis-bio-anvs-director-buys-34000-shares-is-this-the-biggest-insider-bullish-signal-of-2025/ https://twitter.com/i/web/status/1993552531105235305"  
[X Link](https://x.com/BioTechHealthX/status/1993552531105235305)  2025-11-26T05:28Z [---] followers, [---] engagements


"$ACHC Litigation costs surged for Acadia Healthcare (NASDAQ:ACHC) forcing updated [----] guidance and liability reserves up to $165M. But the behavioral health giant still projects over $600M in EBITDA. Dive into the real numbers behind the noise and why analysts see a potential recovery story unfolding. https://biotechhealthx.com/biotech-news/acadia-healthcare-achc-faces-168-spike-in-claims-investors-ask-panic-or-massive-buying-opportunity/ https://twitter.com/i/web/status/1996014208375554256"  
[X Link](https://x.com/BioTechHealthX/status/1996014208375554256)  2025-12-03T00:30Z [---] followers, [---] engagements


"$AXSM AXSM stock has skyrocketed this year yet commercial uncertainty pipeline dependency and competitive headwinds persist. Discover the bearish indicators suggesting @axsome's future returns may fall short of current market expectations. https://biotechhealthx.com/biotech-news/dont-let-the-70-7-ytd-jump-fool-you-axsome-therapeutics-axsm-still-faces-massive-downside-risk/ https://biotechhealthx.com/biotech-news/dont-let-the-70-7-ytd-jump-fool-you-axsome-therapeutics-axsm-still-faces-massive-downside-risk/"  
[X Link](https://x.com/BioTechHealthX/status/1996027597256626232)  2025-12-03T01:23Z [---] followers, [---] engagements


"$WST Analysts expect strong future earnings from West Pharmaceutical Services (NYSE:WST) due to high-value product expansion GLP-1 demand and operational efficiencies. See why this $350.77 price target could be achievable sooner than the market believes. https://biotechhealthx.com/biotech-news/west-pharmaceutical-services-wst-could-outperform-as-analysts-project-350-77-price-target/ https://biotechhealthx.com/biotech-news/west-pharmaceutical-services-wst-could-outperform-as-analysts-project-350-77-price-target/"  
[X Link](https://x.com/BioTechHealthX/status/1996027724595634479)  2025-12-03T01:24Z [---] followers, [--] engagements


"$OCUL Ocular Therapeutix Inc (NASDAQ:OCUL) shocked the market with plans to file AXPAXLI using only Phase [--] SOL [--] year-one data. With a stunning 382% three-year return and a 16.4% monthly jump analysts say OCUL remains massively undervalued as the wet AMD market shifts toward long-acting therapy. https://biotechhealthx.com/biotech-news/ocular-therapeutix-ocul-surges-382-in-3-years/ https://biotechhealthx.com/biotech-news/ocular-therapeutix-ocul-surges-382-in-3-years/"  
[X Link](https://x.com/BioTechHealthX/status/1997979719359484097)  2025-12-08T10:41Z [---] followers, [---] engagements


"$ATHA The pivot of the century is here. @athirapharma Inc. (NASDAQ: ATHA) has abandoned its old path to snatch a "ready-to-go" Phase [--] breast cancer drug. With a market opportunity of $15.9 billion see why ATHA stock is no longer a gamble but a strategic "Strong Buy" for the [----] healthcare bull run. https://biotechhealthx.com/biotech-news/forget-alzheimers-athira-pharma-atha-just-found-a-multi-billion-dollar-cure/ https://biotechhealthx.com/biotech-news/forget-alzheimers-athira-pharma-atha-just-found-a-multi-billion-dollar-cure/"  
[X Link](https://x.com/BioTechHealthX/status/2002771177501266001)  2025-12-21T16:00Z [---] followers, [--] engagements


"$CADL @Nasdaq - Investors are rushing into Candel Therapeutics Inc. (NASDAQ:CADL) after shocking Phase [--] data revealed survival rates for lung cancer more than doubled historical benchmarks. With a pivotal Phase [--] launch scheduled for Q2 [----] find out why CADL is the "must-watch" stock for anyone tracking the future of immunotherapy and viral oncology on the NASDAQ. https://biotechhealthx.com/biotech-news/the-in-situ-miracle-why-candel-therapeutics-cadl-just-doubled-life-expectancy/"  
[X Link](https://x.com/BioTechHealthX/status/2002771375564722217)  2025-12-21T16:01Z [---] followers, [---] engagements


"$EYPT Individual investors are stunned as @EyePointPharma Inc. (NASDAQ: EYPT) receives "Strong Buy" upgrades from top-tier firms like TD Cowen and Cantor Fitzgerald. With institutional giants owning 99% of the float find out why DURAVYU is poised to replace monthly eye injections and what the $39 price target means for your [----] portfolio. https://biotechhealthx.com/biotech-news/the-eye-injection-killer-why-eyepoint-eypt-just-triggered-a-massive-strong-buy/ https://biotechhealthx.com/biotech-news/the-eye-injection-killer-why-eyepoint-eypt-just-triggered-a-massive-strong-buy/"  
[X Link](https://x.com/BioTechHealthX/status/2002780396925473051)  2025-12-21T16:37Z [---] followers, [---] engagements


"$UNCY @unicycive Therapeutics Inc (NASDAQ:UNCY) is a clinical-stage biotechnology company developing treatments for kidney diseases led by oxylanthanum carbonate an investigational phosphate binding agent developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Heres why investors are tracking UNCY shares the companys background and the key approval timeline shaping the stock narrative. https://biotechhealthx.com/biotech-news/unicycive-therapeutics-uncy-targets-dialysis-pill-burden-with-a-next-gen-phosphate-binding-agent/"  
[X Link](https://x.com/BioTechHealthX/status/2005081501327937776)  2025-12-28T01:00Z [---] followers, [---] engagements


"$XERS Xeris Biopharma Holdings Inc. (NASDAQ:XERS) is transitioning from a risky biotech into a profitable specialty pharma business with proprietary formulation technology growing revenues and expanding margins. Heres why investors are starting to pay attention. https://biotechhealthx.com/biotech-news/this-company-is-quietly-becoming-a-cash-machine-heres-why-xeris-biopharma-xers-is-turning-heads/ https://biotechhealthx.com/biotech-news/this-company-is-quietly-becoming-a-cash-machine-heres-why-xeris-biopharma-xers-is-turning-heads/"  
[X Link](https://x.com/BioTechHealthX/status/2006363440877646312)  2025-12-31T13:54Z [---] followers, [---] engagements


"$AXSM @axsome Therapeutics Inc (NASDAQ:AXSM) is a central nervous system biopharma stock quietly advancing novel treatments for depression narcolepsy and neurological disorders with regulatory momentum and long-term growth potential that could surprise the market. https://biotechhealthx.com/biotech-news/wall-street-isnt-watching-this-cns-stock-yet-but-axsome-therapeutics-axsm-might-be-the-breakout/ https://twitter.com/i/web/status/2006363589645652115 https://biotechhealthx.com/biotech-news/wall-street-isnt-watching-this-cns-stock-yet-but-axsome-therapeutics-axsm-might-be-the-breakout/"  
[X Link](https://x.com/BioTechHealthX/status/2006363589645652115)  2025-12-31T13:55Z [---] followers, [--] engagements


"$UNCY @unicycive Therapeutics Inc. (NASDAQ:UNCY) is developing new treatments for chronic kidney disease and dialysis patients focusing on hyperphosphatemia and real-world patient adherence. Heres why this small biotech company is gaining attention. https://biotechhealthx.com/biotech-news/this-kidney-disease-biotech-is-quietly-targeting-a-billion-dollar-problem-unicycive-therapeutics-uncy-explained/ https://biotechhealthx.com/biotech-news/this-kidney-disease-biotech-is-quietly-targeting-a-billion-dollar-problem-unicycive-therapeutics-uncy-explained/"  
[X Link](https://x.com/BioTechHealthX/status/2006371295806755314)  2025-12-31T14:26Z [---] followers, [---] engagements


"$VVOS With FDA-cleared devices a growing network of sleep centers and strong patient preference trends Vivos Therapeutics Inc (NASDAQ:VVOS) may be quietly building one of healthcares most disruptive platforms in airway health. https://biotechhealthx.com/biotech-news/why-some-investors-think-vivos-therapeutics-vvos-could-be-the-next-big-disruptor-in-sleep-medicine/ https://biotechhealthx.com/biotech-news/why-some-investors-think-vivos-therapeutics-vvos-could-be-the-next-big-disruptor-in-sleep-medicine/"  
[X Link](https://x.com/BioTechHealthX/status/2007865327154328004)  2026-01-04T17:22Z [---] followers, [---] engagements


"$VTYX Ventyx Biosciences (NASDAQ:VTYX) is developing oral therapies for inflammatory and neurodegenerative diseases and buyout rumors involving Eli Lilly are putting VTYX stock firmly on the biotech investor radar. https://biotechhealthx.com/biotech-news/ventyx-biosciences-vtyx-could-be-the-next-billion-dollar-biotech-buyout/ https://biotechhealthx.com/biotech-news/ventyx-biosciences-vtyx-could-be-the-next-billion-dollar-biotech-buyout/"  
[X Link](https://x.com/BioTechHealthX/status/2008905095468196167)  2026-01-07T14:14Z [---] followers, [--] engagements


"$OCUL Ocular Therapeutix Inc. (NASDAQ:OCUL) is redefining ophthalmology with sustained-release drug delivery that replaces daily eye drops. This deep dive explores why OCUL stock could benefit from long-term shifts in eye care and biotech innovation. https://biotechhealthx.com/biotech-news/ocular-therapeutix-ocul-is-quietly-changing-how-eye-diseases-are-treated/ https://biotechhealthx.com/biotech-news/ocular-therapeutix-ocul-is-quietly-changing-how-eye-diseases-are-treated/"  
[X Link](https://x.com/BioTechHealthX/status/2009500354568978434)  2026-01-09T05:39Z [---] followers, [---] engagements


"$MRK @Merck & Co. Inc. (NYSE:MRK) combines blockbuster cancer drugs a deep research pipeline and global scale making it one of the most resilient and strategically positioned pharmaceutical companies in the world. https://biotechhealthx.com/biotech-news/why-merck-co-mrk-could-be-the-safest-growth-stock-in-global-healthcare/ https://biotechhealthx.com/biotech-news/why-merck-co-mrk-could-be-the-safest-growth-stock-in-global-healthcare/"  
[X Link](https://x.com/BioTechHealthX/status/2009500576061837506)  2026-01-09T05:40Z [---] followers, [--] engagements


"$GPCR After licensing news and new clinical trials Structure Therapeutics (NASDAQ:GPCR) has caught investor attention. Heres whats behind the move and what the company is really building. https://biotechhealthx.com/biotech-news/heres-why-structure-therapeutics-gpcr-suddenly-become-a-hot-biotech-stock/ https://biotechhealthx.com/biotech-news/heres-why-structure-therapeutics-gpcr-suddenly-become-a-hot-biotech-stock/"  
[X Link](https://x.com/BioTechHealthX/status/2011119488515928294)  2026-01-13T16:53Z [---] followers, [---] engagements


"$RCEL From burn units to trauma centers @AvitaMedical is redefining wound care with regenerative technology. Discover why NASDAQ:RCEL keeps gaining attention in healthcare investing circles. https://biotechhealthx.com/biotech-news/this-nasdaq-stock-is-turning-skin-healing-into-a-business-meet-avita-medical-rcel/ https://biotechhealthx.com/biotech-news/this-nasdaq-stock-is-turning-skin-healing-into-a-business-meet-avita-medical-rcel/"  
[X Link](https://x.com/BioTechHealthX/status/2012948064533664137)  2026-01-18T17:59Z [---] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing